Frequencies of ABCB1 Gene Variant Alleles and Their Role in Response to Antipsychotic Therapy in Patients with Schizophrenia Spectrum Disorders: Narrative Review
https://doi.org/10.52667/2712-9179-2026-6-1-15-30
Abstract
The ABCB1 transporter protein (also known as P-glycoprotein, P-gp) plays a crucial role in the pharmacokinetics of antipsychotics (APs), determining their bioavailability and distribution in the body. The ABCB1 genetic polymorphisms significantly contributes to interindividual dif-ferences in response to AP therapy in patients with schizophrenia spectrum disorders (SSDs). Increased P-gp functional activity is associated with the development of pseudoresistance to APs, while decreased activity is linked to the development of AP-induced adverse drug reactions. This review aims to systematize current data on the population frequencies of ABCB1 gene allelic variants that influence the activity of P-gp and to establish a scientific foundation for the devel-opment of domestic, ethnically-oriented pharmacogenetic diagnostic test systems. A search was conducted in the databases PubMed, eLIBRARY.RU, Google Scholar, PharmGKB, DrugBank, the Geography of Genetic Variants Browser, ClinVar, dbSNP, SNPedia, Drugs@FDA, Russian State Register of Medicines, the Database of Population Frequencies of Genetic Variants in the Russian Population, the RUSeq Browser, The Rubricator of Clinical Recommendations. Available data on the population frequencies of the most extensively studied high-function (n = 5), low-function (n = 15), and loss-of-function (n = 5) allelic variants of the ABCB1 gene were retrieved and analyzed. The frequency of variant alleles of the ABCB1 gene is heterogeneous across different global populations, a critical factor to consider in the development of pharmacogenetic diagnostic test systems. The ethno-territorial heterogeneity of the Russian gene pool necessitates the develop-ment and subsequent validation of local (region-specific) pharmacogenetic diagnostic test sys-tems, based on large-scale population studies conducted within specific administrative-territorial units.
About the Authors
Natalia A. ShnayderRussian Federation
Tel.: +7-(812)-670-02-20
St. Petersburg 192019; Krasnoyarsk 660022
Ekaterina I. Glushchenko
Russian Federation
St. Petersburg 192019
Anastasia A. Abramenko
Russian Federation
St. Petersburg 192019
Evgeniya K. Kaisinova
Russian Federation
St. Petersburg 192019
Asiyat M. Shirukova
Russian Federation
St. Petersburg 192019
Ilya L. Glushchenko
Russian Federation
Novosibirsk 630091
Regina F. Nasyrova
Russian Federation
St. Petersburg 192019
References
1. Lyman M., McCutcheon R.A. Antipsychotic drugs at 75: the past, present, and future of psychosis management. Br Med Bull. 2025; 156(1): ldaf016. https://doi.org/10.1093/bmb/ldaf016
2. Hart X.M., Gründer G., Ansermot N., et al. Optimisation of pharmacotherapy in psychiatry through therapeutic drug mon-itoring, molecular brain imaging and pharmacogenetic tests: Focus on Antipsychotics. World J Biol Psychiatry. 2024; 25(9): 451-536. https://doi.org/10.1080/15622975.2024.2366235
3. Nasyrova R.F., Shnayder N.A., Osipova S.M., et al. Genetic predictors of antipsychotic efflux impairment via blood-brain barrier: role of transport proteins. Genes (Basel). 2023; 14(5): 1085. https://doi.org/10.3390/genes14051085
4. Paul P.R., Mishra M.K., Bora S., et al. The impact of P-glycoprotein on CNS drug efflux and variability in response. J Biochem Mol Toxicol. 2025; 39(3): e70190. https://doi.org/10.1002/jbt.70190
5. Shnayder N.A., Abdyrakhmanova A.K., Nasyrova R.F. Phase I of antipsychotics metabolism and its pharmacogenetic testing. Personalized Psychiatry and Neurology. 2022; 2(1): 4-21. doi:10.52667/2712-9179-2022-2-1-4-21
6. Wang Y., Tu M.-J., Yu A.-M. Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs. Front. Pharmacol. 2024; 15: 1423416. https://doi.org/10.3389/fphar.2024.1423416
7. DrugBank. Available online: https://go.drugbank.com/ (accessed on 3 December 2025)
8. PharmGKB. Available online: https://www.clinpgx.org/ (accessed on 3 December 2025)
9. Drugs@FDA: FDA-Approved Drugs. Available online: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed on 1 December 2025)
10. Russian State Register of Medicines. Available online: https://grls.minzdrav.gov.ru/Default.aspx (accessed on 1 December 2025) (In Russian)
11. Elmeliegy M., Vourvahis M., Guo C., et al. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug–drug interaction studies. Clin Pharmacokinet. 2020; 59: 699–714. https://doi.org/10.1007/s40262-020-00867-1
12. Husain A., Makadia V., Valicherla G.R., et al. Approaches to minimize the effects of P‐glycoprotein in drug transport: A review. Drug development research, 2022; 83(4): 825-841. https://doi.org/10.1002/ddr.21918
13. Caudle K. E., Dunnenberger H.M., Freimuth R.R., et al. Standardizing terms for clinical pharmacogenetic test results: con-sensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017; 19(2): 215–223. https://doi.org/10.1038/gim.2016.87
14. Vaiman E.E., Shnayder N.A., Nasyrova R.F., Neznanov N.G. Patent №.2810798 Method of choosing treatment tactics for patients with antipsychotic-induced extrapyramidal disorders: №. 2022126875: stated: 10/14/2022; published: 12/28/2023; applicant, patent holder: V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology. (In Russian)
15. Toja-Camba, F.J., Vidal-Millares, M., Durán-Maseda, M.J. et al. Influence of ABCB1 polymorphisms on aripiprazole and dehydroaripiprazole plasma concentrations. Sci Rep. 2025; 15: 1521. https://doi.org/10.1038/s41598-024-84192-8
16. Shnayder N.A., Grechkina V.V., Arkhipov V.V., Nasyrova R.F. Role of pharmacogenetic testing in the risk and safety as-sessment of valproates: the ethnic aspect (review). Safety and Risk of Pharmacotherapy. 2024; 12(2): 132–154. (In Russian) https://doi.org/10.30895/2312-7821-2024-12-2-132-154
17. Bairova T.A., Nemchinova N.V., Belyaeva E.V., et al. The prevalence of polymorphic variants of ABCB1 gene among in-digenous populations of Siberia. Russ J Genet. 2022; 58: 57–64. (In Russian) https://doi.org/10.1134/S1022795421110028
18. Nasyrova R.F., Osipova S.M., Shnayder N.A., Abdrykhmanova A.K., Neznanov N.G. Patent № 2821045 Russian Federation. Method for choosing treatment tactics for patients with mental disorders: no. 2022108385; filed March 29, 2022; published June 17, 2024; applicant and patent owner: V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology (In Russian)
19. Geography of Genetic Variants Browser. Available online: https://popgen.uchicago.edu/ggv/ (accessed on 2 December 2025)
20. Database of population frequencies of genetic variants in the population of the Russian Federation. Available online: https://nir.cspfmba.ru/ (accessed on 2 December 2025)
21. RUSeq – a project to pool genetic information between clinical laboratories and genomic centers in Russia. Available online: http://ruseq.ru/#/ (accessed on 2 December 2025)
22. Sychev D.A., Chernyaeva M.S., Ostroumova O.D. Genetic risk factors for adverse drug reactions. Safety and Risk of Pharma-cotherapy 2022; 10(1): 48–64. (In Russian) https://doi.org/10.30895/2312-7821-2022-10-1-48-64
23. Howes O.D., Thase M.E., Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry, 2022; 27(1): 58–72. https://doi.org/10.1038/s41380-021-01200-3
24. Russian Clinical Practice Guidelines "Schizophrenia" 2024. Available online: https://cr.minzdrav.gov.ru/preview-cr/451_3 (accessed on 1 December 2025)
25. Taylor D.M., Thomas R.E., Barnes T.R.E., Young A.H. The Maudsley Prescribing Guidelines in Psychiatry, 14th Edition. John Wiley & Sons, Inc.: 111 River Street, Hoboken, NJ 07030, USA, 2021, pp. 96–97.
26. Jobson K. International psychopharmacology algorithm project: algorithms in psychopharmacology. Int J Psychiatry Clin Pract. 1997; 1 Suppl 1: S3. https://doi.org/10.3109/13651509709024748
27. Verma S., Chan L.L., Chee K.S., et al. Clinical Practice Guidelines Workgroup on Schizophrenia. Ministry of Health clinical practice guidelines: schizophrenia. Singapore Med J. 2011; 52(7): 521-526.
28. Howes O.D., McCutcheon R., Agid O. et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017; 174(3): 216-229. https://doi.org/10.1176/appi.ajp.2016.16050503
29. Galletly C., Castle D., Dark F., et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016; 50(5): 410-472. https://doi.org/10.1177/0004867416641195
30. Hasan A., Falkai P., Wobrock T., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Bio-logical Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5): 318-378. https://doi.org/10.3109/15622975.2012.696143
31. Nasyrova R.F., Dobrodeeva V.S., Skopin S.D., et al. Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation. Bulletin of Neurology, Psychiatry and Neurosurgery. 2020; 3; 6-12 (In Russian)
32. Zakharova N.V., Nasyrova R.F. Towards personalized psychiatry: Foreign experience in psychopharmacogenetics. Lex Ge-netica. 2025; 4(2): 76-93. (In Russian) https://doi.org/10.17803/lexgen-2025-4-2-76-93
33. Sasabe H., Koga T., Furukawa M., et al. In vitro evaluations for pharmacokinetic drug-drug interactions of a novel seroto-nin-dopamine activity modulator, brexpiprazole. Xenobiotica, 2021; 51(5): 522–535. https://doi.org/10.1080/00498254.2021.1897898
34. Balanovskaya E.V., Gorin I.O., Ponomarev G.Yu., et al. Genogeographic technologies of a population biobank as a tool for assessing selection effects (using the example of pharmacogenetic biomarkers of cardiovascular diseases). Cardiovascular Therapy and Prevention 2023; 22(11): 3773. (In Russian) https://doi.org/10.15829/1728-8800-2023-3773. EDN XPMFOW
35. Shnayder N.A., Vaiman E.E., Nasyrova R.F. Antipsychotic-induced parkinsonism: A Risk Assessment Scale and Personalised Diagnosis Algorithm. Safety and Risk of Pharmacotherapy 2025; 13(1): 70-85. (In Russian) https://doi.org/10.30895/2312-7821-2024-418
36. Spektor E.D., Yudin V.S., Mamchur A.A., et al. Pharmacogenetic factors determining the metabolism and safety of aromatic anticonvulsants in the residents of Russia. Extreme Medicine. (In Russian) https://doi.org/10.47183/mes.2025-364
37. Sychev D.A., Mirzaev K.V., Denisenko N.P., et al. Pharmacogenetic biomarker factory: how does it work? Russian Journal for Personalized Medicine 2021; 1(1): 33-42. (In Russian) https://doi.org/615.1
Review
For citations:
Shnayder N.A., Glushchenko E.I., Abramenko A.A., Kaisinova E.K., Shirukova A.M., Glushchenko I.L., Nasyrova R.F. Frequencies of ABCB1 Gene Variant Alleles and Their Role in Response to Antipsychotic Therapy in Patients with Schizophrenia Spectrum Disorders: Narrative Review. Personalized Psychiatry and Neurology. 2026;6(1):15-30. https://doi.org/10.52667/2712-9179-2026-6-1-15-30
JATS XML












